Amgen Slips as Gene-Targeting Drug Misses Some ‘Lofty Hopes’

(Bloomberg) -- More than half of patients with an advanced form of lung cancer initially responded to an experimental drug from Amgen Inc. that targets a genetic driver of the disease previously co...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.